MedTrace Logo

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

NCT04867603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2023-12-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen (\[Ga-68\]PSMA) for characterization of prostate abnormalities.

Conditions

Interventions

DRUG

[Ga-68]PSMA

The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.

DEVICE

PET/CT imaging

PET/CT imaging procedure

Sponsors & Collaborators

  • Norbert Avril, M.D.

    lead OTHER

Principal Investigators

  • Norbert Avril, MD · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2022-10-03
Completion
2022-10-03
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04867603 on ClinicalTrials.gov